JATT III Acquisition Corp closes $69M IPO on Nasdaq

JATT III Acquisition Corp closed its initial public offering of 6,900,000 ordinary shares at $10.00 per share, raising $69,000,000 in gross proceeds before underwriting discounts, commissions, and other expenses, according to a press release from the company.

The offering included 900,000 additional ordinary shares issued following the full exercise of the underwriters' over-allotment option. The ordinary shares began trading on the Nasdaq Global Market under the ticker symbol NASDAQ: JTTT on Aug. 26, 2026, with the offering closing on Aug. 27, 2026.

Guggenheim Securities, LLC served as sole book-running manager. The U.S. Securities and Exchange Commission declared the registration statement effective on Aug. 25, 2026.

Institutional investors participating in the offering included Adage Capital Partners, L.P., ADAR1 Capital, Affinity Asset Advisors, Columbia Threadneedle Investments, Deep Track Capital, Great Point Partners, Janus Henderson Investors, Nantahala Capital, RA Capital Management, Sirenia Capital Management LP, and Squadron Capital Management.

AI Biotechnology LLC, an affiliate of Access Industries, Inc., and Vianti Capital Fund I, L.P. indicated non-binding interests to participate in a private placement that may occur alongside the company's initial business combination.

JATT III Acquisition Corp is a blank check company incorporated in the Cayman Islands, focused on identifying a merger or acquisition target in healthcare, with an emphasis on biotechnology and life sciences. The company has not identified a specific business combination target.

You May Also Be Interested In

• DeFi Development Corp. plans $20M preferred stock offering
• Helix and Hornbeck complete all-stock merger, form new NYSE: HOS
• S&P Global completes sale of energy software portfolio to SLB